Papers
6
Total Citations
24
H-Index
3
About
David Pfister is a leading urologic oncologist whose research centers on advanced surgical management of testicular and prostate cancers, with a particular focus on minimizing long-term treatment toxicities. His most impactful contribution is pioneering primary retroperitoneal lymph node dissection (RPLND) for stage II seminoma, as demonstrated in the landmark SWENOTECA and Cologne study (2023, 7 citations). This work challenges traditional chemotherapy and radiotherapy standards by offering a surgical alternative that maintains excellent survival while reducing significant long-term side effects. Pfister has also advanced robotic-assisted urologic surgery, including radical prostatectomy in elderly patients and complex reconstructive procedures like ileal ureter replacement. His expertise extends to salvage vesiculectomy for recurrent prostate cancer and post-chemotherapy RPLND for testicular seminoma, with recent findings from two large referral centers (2024). With a career spanning over a decade, Pfister’s research consistently emphasizes surgical innovation to improve oncologic outcomes and quality of life, making him a key figure in the shift toward less toxic, surgery-first approaches for genitourinary malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2Roboterassistierte radikale Prostatektomie beim älteren Patienten6 citations · 2012
- 3Peritonealkarzinose nach roboterassistierter radikaler Zystektomie4 citations · 2011
- 4
- 5
- 6